- Home
- CLLS vs RENE Comparison
CLLS vs RENE Comparison
Compare CLLS & RENE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CLLS
- RENE
- Stock Information
- Founded
- CLLS 1999
- RENE 2021
- Country
- CLLS France
- RENE United States
- Employees
- CLLS N/A
- RENE N/A
- Industry
- CLLS Biotechnology: Pharmaceutical Preparations
- RENE Blank Checks
- Sector
- CLLS Health Care
- RENE Finance
- Exchange
- CLLS Nasdaq
- RENE Nasdaq
- Market Cap
- CLLS 240.2M
- RENE 243.8M
- IPO Year
- CLLS 2007
- RENE 2022
- Fundamental
- Price
- CLLS $1.89
- RENE $11.47
- Analyst Decision
- CLLS Buy
- RENE
- Analyst Count
- CLLS 2
- RENE 0
- Target Price
- CLLS $8.00
- RENE N/A
- AVG Volume (30 Days)
- CLLS 22.5K
- RENE 51.8K
- Earning Date
- CLLS 11-04-2024
- RENE 01-01-0001
- Dividend Yield
- CLLS N/A
- RENE N/A
- EPS Growth
- CLLS N/A
- RENE N/A
- EPS
- CLLS N/A
- RENE 0.36
- Revenue
- CLLS $19,635,000.00
- RENE N/A
- Revenue This Year
- CLLS $271.02
- RENE N/A
- Revenue Next Year
- CLLS $33.48
- RENE N/A
- P/E Ratio
- CLLS N/A
- RENE $32.01
- Revenue Growth
- CLLS N/A
- RENE N/A
- 52 Week Low
- CLLS $0.96
- RENE $10.80
- 52 Week High
- CLLS $3.77
- RENE $11.58
- Technical
- Relative Strength Index (RSI)
- CLLS 30.12
- RENE 78.28
- Support Level
- CLLS $1.95
- RENE $11.40
- Resistance Level
- CLLS $2.08
- RENE $11.48
- Average True Range (ATR)
- CLLS 0.11
- RENE 0.01
- MACD
- CLLS -0.04
- RENE -0.00
- Stochastic Oscillator
- CLLS 0.00
- RENE 80.00
About CLLS Cellectis S.A.
Cellectis SA is a clinical stage biotechnological company, employing the core proprietary technologies to develop products based on gene-editing, with a portfolio of allogeneic Chimeric Antigen Receptor T-cells, or UCART, product candidates in the field of immuno-oncology and gene-edited hematopoietic stem and progenitor cells, or HSPC, product candidates in other therapeutic indications.
About RENE Cartesian Growth Corporation II
Cartesian Growth Corp II is a blank check company.